Human use: how was it informed by canine comparative oncology data? The lack of apparent toxicities and efficacy demonstrated by a highly significant increase in tumor control and survival time confirmed clinical responses in pet dogs with naturally occurring malignant glioma garnered enthusiasm for initiation of a Phase I dose-escalation clinical trial for recurrent glioblastoma in adults ( NCT04642937 ).
1
—
—